Using previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to plan simple palliative radiation treatments can substantially reduce the time some people spend waiting for urgent treatment, improving the patient experience, a new study suggests.
A novel liquid biopsy test may help determine which patients with non-small cell lung cancer that has spread beyond the lungs are most likely to benefit from targeted, high-dose radiation, rather than drug-based therapy, a new study suggests.
A type of head and neck cancer predominantly diagnosed in people who reside in low- and middle-income countries may be treated effectively with fewer, but higher doses of radiation, a large new international study suggests.
The presence of a clinical navigator to act as a liaison between people with prostate cancer and the health care system greatly increases the likelihood that patients, especially Black patients, will receive advanced testing that can help predict the severity of their disease and guide treatment, a new study suggests.
In a first-of-its-kind study, people with breast cancer who underwent implant-based breast reconstruction immediately following a mastectomy reported that getting fewer, higher doses of radiation was just as effective as standard radiation, did not increase side effects and saved them time and money.
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests.
People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical cancer are at lower risk for long-term side effects, according to a new study from researchers in Austria.
Two liquid biopsy tests that look for the presence of human papillomavirus (HPV) in the blood accurately identified patients with a high risk of cervical cancer recurrence after the completion of chemoradiation, a new study confirms.
People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests.
The American Society for Radiation Oncology (ASTRO) today announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.
The American Society for Radiation Oncology (ASTRO) announced today the 10 studies to be highlighted in the 2023 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held October 2 and 3 at the San Diego Convention Center and via live webcast.
American Society for Radiation Oncology (ASTRO) President Jeff Michalski, MD, MBA, FASTRO, will join today’s first stakeholder meeting of the President’s Cancer Panel. Dr. Michalski was invited to share how ASTRO and the radiation oncology community are contributing to the National Cancer Plan. Radiation therapy contributes to 40% of global cancer cures, and more than a million Americans receive radiation treatments for cancer each year.
The American Society for Radiation Oncology (ASTRO) selected 29 distinguished members to receive the ASTRO Fellow (FASTRO) designation for its 2023 class of Fellows. These physician leaders will be recognized at an awards ceremony in San Diego on Tuesday, October 3 during ASTRO's 65th Annual Meeting. The ASTRO Fellows program recognizes individuals who have made substantial contributions to the Society and to the field of radiation oncology through research, education, patient care and service to the field.
The members of the American Society for Radiation Oncology (ASTRO) recently elected three new officers to ASTRO’s Board of Directors, including Sameer Keole, MD, FASTRO, as President-elect; Wendy Woodward, MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S. Kavadi, MD, MBA, FASTRO, as Health Policy Council Vice Chair.
The American Society for Radiation Oncology (ASTRO) issued the following statement from Geraldine M. Jacobson, MD, MBA, MPH, FASTRO, Chair of the ASTRO Board of Directors, in response to the proposed 2024 Medicare Physician Fee Schedule (MPFS) released today: “Another year brings another round of cuts to radiation therapy services for people with cancer under the proposed Medicare fee schedule."
The American Society for Radiation Oncology (ASTRO) Gastrointestinal Cancers Resource Panel issued a statement today on the PROSPECT clinical trial for patients with locally advanced rectal cancer. The statement clarifies that the trial did not explicitly conclude that radiation therapy should be omitted, contrary to many news reports, but rather that patients now have an additional treatment option to consider in discussions with their care team.
More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages, according to a new national survey from the American Society for Radiation Oncology (ASTRO). More than half (53%) of the doctors said the shortages are creating treatment delays for patients, and 44% say they are causing increased patient anxiety.
Registration opens today for the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting, which will be held at the San Diego Convention Center, October 1-4, 2023. Media registration is available at www.astro.org/astro2023press, and general registration is available at www.astro.org/annualmeeting.
The American Society for Radiation Oncology (ASTRO) today expressed its strong support for President Joseph R. Biden Jr.’s nomination of Monica Bertagnolli, MD, as director of the National Institutes of Health (NIH) with the following statement from Geraldine M. Jacobson, MD, MBA, MPH, FASTRO, Chair of the ASTRO Board of Directors.
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy & Oncology (ESTRO) provides guidance on the use of definitive local therapy—including radiation and surgery—to treat patients with oligometastatic non-small cell lung cancer (NSCLC). The guideline is published in Practical Radiation Oncology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right